Table 2 Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI), biannual ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the magnitude of the assumed anti-macrofilarial action of ivermectin and moxidectin
Baseline endemicity level (microfilarial prevalence) | 1% cumulative reduction in microfilarial production by female adult worms per dose | 7% cumulative reduction in microfilarial production by female adult worms per dose | 30% cumulative reduction in microfilarial production by female adult worms per dose | ||||||
|---|---|---|---|---|---|---|---|---|---|
Projected duration, in years, of treatment programme (relative cost, in percent) | Projected duration, in years, of treatment programme (relative cost, in percent) | Projected duration, in years, of treatment programme (relative cost, in percent) | |||||||
aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | |
Mesoendemic (40%) | 21 | 14 (118%) | 12 (65%, 55%) | 17 | 11 (113%) | 11 (71%, 63%) | 12 | 9 (126%) | 10 (86%, 68%) |
Hyperendemic (60%) | 33 | 20 (115%) | 18 (67%, 58%) | 25 | 16 (116%) | 17 (76%, 66%) | 17 | 14 (138%) | 15 (91%, 66%) |
Highly-hyperendemic (80%) | NA | 38 (140%) | 30 (76%, 54%) | NA | 26 (112%) | 26 (70%, 63%) | 38 | 22 (114%) | 23 (74%, 65%) |